Oncotelic therapeutics inc stock is down -100% since 30 days ago. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25.81% of the previous 30 December’s closed higher than November.
Oncotelic Therapeutics, Inc. engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma. It also develops OXi4503 for the. treatment of acute myeloid leukemia and myelodysplastic syndromes.